Lundbeck maintains its guidance for 2021 since the company's first quarter ended significantly better than what the market had expected.
In total, Lundbeck landed at a DKK 4.274bn (USD 698.8m) revenue, down from the DKK 4.564bn the company secured in the first three months of 2020. It should, however, be taken into consideration that at this point, the firm was positively affected by stockpiling owing to the Covid-19 pandemic. Nevertheless, this is better than the DKK 4.208bn which analysts estimated.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Clinical Trial Manager - Genmab 
Principal Biostatistician - ALK 
Chief Physician - Clinical Innovation Centre, Novo Nordisk 
Associate Director, PV/GCP Quality Assurance - Y-mAbs Therapeutics 
Employee for regulatory department 
Senior Clinical Development Scientist/Physician - Lundbeck 
eTMF Manager - Klifo 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
Regulatory affairs life cycle specialist 
(Senior) Regulatory Science Specialist - IWA Consulting